Pathstone Holdings LLC Cuts Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Pathstone Holdings LLC cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 8.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,677 shares of the biopharmaceutical company's stock after selling 1,254 shares during the quarter. Pathstone Holdings LLC's holdings in Regeneron Pharmaceuticals were worth $9,743,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of REGN. Pamalican Asset Management Ltd bought a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $4,915,000. Intact Investment Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $356,000. Rhenman & Partners Asset Management AB increased its holdings in shares of Regeneron Pharmaceuticals by 11.4% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock worth $30,956,000 after buying an additional 4,457 shares in the last quarter. Fagan Associates Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 42.2% during the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock worth $9,205,000 after buying an additional 3,832 shares in the last quarter. Finally, Golden State Equity Partners increased its holdings in shares of Regeneron Pharmaceuticals by 1,479.1% during the fourth quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company's stock worth $967,000 after buying an additional 1,272 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have issued reports on REGN. Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Wells Fargo & Company decreased their price objective on Regeneron Pharmaceuticals from $750.00 to $700.00 and set an "overweight" rating for the company in a research report on Wednesday, April 30th. Bank of America dropped their target price on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a report on Thursday, April 17th. Bernstein Bank lowered their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Finally, Cantor Fitzgerald started coverage on Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 target price for the company. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $890.60.

Regeneron Pharmaceuticals Stock Up 3.1%

REGN traded up $18.25 during midday trading on Tuesday, hitting $614.79. The company had a trading volume of 1,102,019 shares, compared to its average volume of 792,581. Regeneron Pharmaceuticals, Inc. has a 52 week low of $520.50 and a 52 week high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $66.38 billion, a price-to-earnings ratio of 16.06, a PEG ratio of 2.34 and a beta of 0.43. The stock's 50 day moving average price is $598.10 and its 200 day moving average price is $680.17.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company's revenue was down 3.7% on a year-over-year basis. During the same period in the previous year, the firm earned $9.55 earnings per share. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.57%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.